Skip to content
Studies have shown that active fund managers routinely underperform the S&P500 index*
Home
Articles
WALL STREET X
Forecasts
Portfolios
Wall Street X
Articles
Forecasts
Portfolios
Search
Results for
{phrase}
(
{results_count}
of
{results_count_total}
)
Displaying
{results_count}
results of
{results_count_total}
Gyre Therapeutics, Inc. (NASDAQ: GYRE)
GYRE Stock Predictions and Ratings
WSX Rating:
STRONG BUY
WSX Forecast (1yr):
24.60%
Analyst Rating:
STRONG BUY
Analyst Forecast (1yr):
189%
GYRE Stock Analysis
GYRE
PE Ratio:
GYRE
PEG Ratio:
Not Available
GYRE
Forward EPS Growth (12 month):
0.00%
GYRE
PS Ratio:
4.7
GYRE
PSG Ratio:
0.2
GYRE
Forward Revenue Growth (12 month):
29.70%
GYRE Articles
No data was found